Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Retained Earnings (2016 - 2025)

Vanda Pharmaceuticals' Retained Earnings history spans 16 years, with the latest figure at $629000.0 for Q4 2025.

  • For Q4 2025, Retained Earnings rose 100.36% year-over-year to $629000.0; the TTM value through Dec 2025 reached $629000.0, up 100.36%, while the annual FY2025 figure was $629000.0, 100.36% up from the prior year.
  • Retained Earnings for Q4 2025 was $629000.0 at Vanda Pharmaceuticals, up from $540000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $702000.0 in Q3 2024 and bottomed at -$203.8 million in Q1 2025.
  • The 5-year median for Retained Earnings is -$155.0 million (2023), against an average of -$101.4 million.
  • The largest annual shift saw Retained Earnings crashed 90129.14% in 2022 before it soared 172.6% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$175000.0 in 2021, then plummeted by 90129.14% to -$157.9 million in 2022, then grew by 1.59% to -$155.4 million in 2023, then fell by 12.16% to -$174.3 million in 2024, then soared by 100.36% to $629000.0 in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Retained Earnings are $629000.0 (Q4 2025), $540000.0 (Q3 2025), and $396000.0 (Q2 2025).